Actimarbo 5 mg Flavoured Tablets for Dogs and Cats

Main information

  • Trade name:
  • Actimarbo 5 mg Flavoured Tablets for Dogs and Cats
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Actimarbo 5 mg Flavoured Tablets for Dogs and Cats
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Cats Non Food, Dogs Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0461/001
  • Authorization date:
  • 26-06-2013
  • EU code:
  • UK/V/0461/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:August2013

AN:00513/2012

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Actimarbo5mgFlavouredTabletsforDogsandCats(AT,CZ,DE,ES,IT,NL,PT,SK,

UK)

Actimarbo5mgTabletsforDogsandCats(FR)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Marbofloxacin 5.0mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet.

Off-whitetobeigebrownspotted,round,uncoatedtabletembossed “MV”and“5”on

eithersideofbreaklineononesideandplainonotherside.

Thetabletscanbedividedintohalves.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogsandcats.

4.2Indicationsforuse,specifyingthetargetspecies

Indogs

Marbofloxacinisindicatedinthetreatmentof:

Skinandsofttissueinfectionscausedbysusceptiblestrainsoforganisms.

Urinarytractinfections(UTI)associatedornotwithprostatitisorepididymitiscaused

bysusceptiblestrainsoforganisms.

Respiratoryinfections,causedbysusceptiblestrainsoforganisms.

Issued:August2013

AN:00513/2012

Page2of8

Incats

Marbofloxacinisindicatedinthetreatmentofskinandsofttissueinfections(wounds,

abscesses,phlegmons)andupperrespiratorytractinfectionscausedbysusceptible

strainsoforganisms.

4.3Contraindications

Marbofloxacinshouldnotbeusedindogsagedlessthan12months,orlessthan18

monthsforexceptionallylargebreedsofdogs,suchasGreatDanes,Briard,Bernese,

BouvierandMastiffs,withalongergrowthperiod.Notrecommendedforuseincats

agedlessthan16weeks.

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinorother

(fluoro)quinolonesortoanyoftheexcipientsoftheproduct.

Donotuseincaseofconfirmedorsuspectedresistancetofluoroquinolones(cross

resistance).

4.4Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilageinjuvenile

dogsandcareshouldbetakentodoseaccuratelyespeciallyinyounganimals.

Somefluoroquinolonesathighdosesmayhaveanepileptogenicpotential.Cautious

useisrecommendedindogsandcatsdiagnosedassufferingfromepilepsy.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhichhave

respondedpoorly,orareexpectedtorespondpoorlytootherclassesofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothefluoroquinolonesandmaydecreaseeffectiveness

oftreatmentwithotherquinolonesduetothepotentialforcross-resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidcontactwiththe

veterinarymedicinalproduct.

Incaseofaccidentalingestionseekmedicaladviceimmediatelyandshowthepackage

leafletorthelabeltothephysician.

Issued:August2013

AN:00513/2012

Page3of8

Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Atthetherapeuticrecommendeddosage,nosevereside-effectsaretobeexpectedin

dogsandcats.

Mildsideeffectssuchasvomiting,softeningoffaeces,modificationofthirstortransient

increaseinactivitymayoccasionallyoccur.Thesesignsceasespontaneouslyafter

treatmentanddonotnecessitatecessationoftreatment.

Hypersensitivity(allergic)reactionsmayoccurintreatedanimals.Inthecaseofallergic

reaction,thetreatmentshouldbewithdrawn.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rats,rabbits)showednoteratogenicity,embryotoxicity

andmaternotoxicitywithmarbofloxacinattherapeuticdoses.

Thesafetyofmarbofloxacinhasnotbeenassessedinpregnantandlactatingcatsand

dogs.

Useonlyaccordingtothebenefit/riskassessmentbytheresponsibleveterinarianin

pregnantandlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(Aluminium,

Calcium,Magnesium,Iron).Insuchcases,thebioavailabilitymaybereduced.

Concomitantadministrationoftheophyllinerequirescarefulmonitoringasserumlevels

oftheophyllinemayincrease.

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

Therecommendeddoserateis2mg/kg/d(1tabletfor2.5kgperday)insingledaily

administration.

Species Weight Dose(Numberoftabletsperday)

Actimarbo

5mgtablet Actimarbo

20mgtablet Actimarbo

80mgtablet

Cat ≤1.2kg ½

1.2- ≤2.5kg 1

2.5- ≤3.7kg 1½

3.7- ≤5kg 2

5- ≤6.2kg

6.2- ≤7.5kg 3

Issued:August2013

AN:00513/2012

Page4of8

7.5- ≤8.7kg 3½

8.7- ≤10kg

4

Dog <5kg 2 OR ½

5- ≤10kg 1

10- ≤15kg 1½

15- ≤20kg 2 OR ½

20- ≤25kg 2½

25- ≤30kg 3

30- ≤35kg 3½

35- ≤40kg 4 OR 1

40- ≤60kg 1½

60- ≤80kg 2

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

DOGS:

inskinandsofttissueinfections,treatmentdurationisatleast5days.Dependingon

thecourseofthedisease,itmaybeextendedupto40days.

inurinarytractinfections,treatmentdurationisatleast10days.Dependingonthe

courseofthedisease,itmaybeextendedupto28days.

inrespiratoryinfections,treatmentdurationisatleast7daysanddependingonthe

courseofthedisease,itmaybeextendedupto21days.

CATS:

forskinandsofttissueinfections(wounds,abscesses,phlegmons)treatment

durationis3to5days.

forupperrespiratoryinfectionstreatmentdurationis5days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,whichshould

betreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolones

ATCvetcode:QJ01MA93

Issued:August2013

AN:00513/2012

Page5of8

Issued:August2013

AN:00513/2012

Page6of8

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

groupwhichactsbyinhibitionofDNAgyrase.Itiseffectiveagainstawiderangeof

Grampositivebacteria(includingStreptococciandinparticularStaphylococci)and

Gramnegativebacteria(Escherichiacoli,Enterobactercloacae,Proteusspp,

Klebsiellaspp,Shigellaspp,Pasteurellaspp,Pasteurellaspp,Pseudomonasspp)as

wellasMycoplasmaspp.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.Casesofresistance

havebeenobservedinStreptococcus.

Themarbofloxacininvitroactivityagainstcanineandfelinepathogensisolatedin

Germanybetween2004and2006isgood:MIC

valuesare0.5µg/mlfor

Staphylococcuspseudointermedius,0.03µg/mlforEscherichiacoliand0.06µg/mlfor

Pasteurellamultocida.Str ainswithMIC≤1µg/mlaresensitivetomarbofloxacin

whereasstrainswithMIC≥4µg/mlareresistanttomarbofloxacin.

Resistancetofluoroquinolonesoccursbychromosalmutationwith3mechanisms:

decreaseofbacterialwallpermeability,expressionofeffluxpumpormutationof

enzymesresponsibleformoleculebinding.

Therewasnosignificantdevelopment,evolutionorspreadofresistanceinpathogenic

strainsisolatedfromdiseasesincompanionanimals,sincetheuseofmarbofloxacinon

theveterinarymarket.Theincidenceandthedegreeoftransferofgeneticresistance

maybeconsideredasverylow.

Cross-resistancetobeta-lactamantibiotics,aminoglycosides,tetracyclines,macrolides

andpolypeptideantibiotics,sulfonamides,nitrofuransanddiaminopyrimidinesgenerally

doesnotoccur.However,certainmutationscausingresistancetomarbofloxacin,can

alsocauseresistanceagainstcephalosporins,tetracyclines,macrolidesand

chloramphenicol.

5.2Pharmacokineticparticulars

Afteroraladministrationindogsandcatsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof1.5

µg/mlwithin2hours.

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandin

mosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hindogs

and10hincats)predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

Issued:August2013

AN:00513/2012

Page7of8

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Cellulosemicrocrystalline

PovidoneK90

Purifiedwater

Crospovidone

Meatflavour

Silica,colloidalanhydrous

Magnesiumstearate

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelf-lifeofhalvedtablets:7days.

Seealsosection6.4.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Incaseofusinghalvedtablets:Returnanyremaininghalftablettotheopenedblister

pocket.Usetheremaininghalftabletforthenextadministration.

Seealsosection6.3.

6.5Natureandcompositionofimmediatepackaging

Theproductispackagedinaluminium –PVC/aluminium/polyamideblister.

Boxof1blisterof10tablets

Boxof2blistersof10tablets

Boxof10blistersof10tablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Issued:August2013

AN:00513/2012

Page8of8

7. MARKETINGAUTHORISATIONHOLDER

EcupharNV

Legeweg157-i

8020Oostkamp

Belgium

8. MARKETINGAUTHORISATIONNUMBER

Vm32742/4009

9. DATEOFFIRSTAUTHORISATION

August2013

10.DATEOFREVISIONOFTHETEXT

August2013

PROHIBITIONORSUPPLYSALEANDORUSE

Onveterinaryprescriptiononly.

APPROVED 2/08/13

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration

12-12-2017

Keep Your Dogs and Cats Safe From Holiday Hazards

Keep Your Dogs and Cats Safe From Holiday Hazards

From tinsel to table scraps, holiday hazards for pets abound. Here are some tips to help you keep them safe.

FDA - U.S. Food and Drug Administration